Omics is a rapidly evolving, multi-disciplinary, and emerging field that encompasses genomics, epigenomics, transcriptomics, proteomics, and metabolomics.Advanced omics technologies, including single-cell omics and multi-omics, are being used to evaluate a variety of cancer immunotherapies. Furthermore, given the precision medicine environment, the expanding use of multi-omics in research, as well as the penetration of contemporary sequencing technologies, is boosting the market.
This report contains market size and forecasts of Omics Based Clinical Trials in Global, including the following market information:
Global Omics Based Clinical Trials Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Omics Based Clinical Trials market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Interventional Studies Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Omics Based Clinical Trials include Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer, Covance and Rebus Bio and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Omics Based Clinical Trials companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Omics Based Clinical Trials Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Omics Based Clinical Trials Market Segment Percentages, by Type, 2021 (%)
Interventional Studies
Observational Studies
Expanded Access Studies
Global Omics Based Clinical Trials Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Omics Based Clinical Trials Market Segment Percentages, by Application, 2021 (%)
Oncology
Cardiology
Respiratory Diseases
Skin Diseases
CNS Diseases
Immunology
Genetic Diseases
Other Indications
Global Omics Based Clinical Trials Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Omics Based Clinical Trials Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Omics Based Clinical Trials revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Omics Based Clinical Trials revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Parexel International Corporation
Pharmaceutical Product Development (PPD)
Charles River Laboratory
ICON plc
SGS SA
Eli Lilly and Company
Pfizer
Covance
Rebus Bio
Novo Nordisk